Antibody-Drug Conjugates (ADCs) in Oncology Pipeline Analysis 2025: DelveInsight Unveils Competitive Landscape Report 2025 Covering 200+ Companies and 220+ Drugs Worldwide

Comprehensive insights into one of the fastest-growing classes of targeted cancer therapies, including pipeline assessments, clinical progress, collaborations, and future outlook

[Albany, United States] DelveInsight, a leading business consulting and market research firm in the life sciences sector, has released its latest report, "Antibody-Drug Conjugates (ADCs) - Competitive Landscape, 2025," providing unparalleled insights into the rapidly evolving ADC therapeutics market. The report offers an in-depth analysis of more than 200 companies and 220+ drugs in the ADC landscape, making it one of the most exhaustive references for stakeholders across the oncology ecosystem.

The coverage spans global geographies and highlights pipeline and marketed products, drug profiles, company overviews, collaborations, licensing activities, and clinical trial updates. The report also delivers an analytical perspective on emerging trends and unmet needs in oncology therapeutics.

Download the Full ADC Competitive Landscape Report Now - Stay Ahead of Oncology Trends - https://www.delveinsight.com/report-store/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Antibody-Drug Conjugates (ADCs): A Revolution in Targeted Cancer Therapy
Antibody-Drug Conjugates (ADCs) are at the forefront of precision oncology, combining the specificity of monoclonal antibodies with the potency of chemotherapy drugs. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, Antibody-Drug Conjugates are designed to selectively deliver cytotoxic payloads to tumor cells, thereby enhancing therapeutic efficacy and minimizing side effects.

An Antibody-Drug Conjugates typically comprises three essential components:
• Antibody - precisely targets antigens overexpressed on tumor cells.
• Cytotoxic Payload - induces cell death via DNA damage or microtubule disruption.
• Linker - ensures stability in circulation and effective release at the tumor site.
This sophisticated mechanism of action includes antigen recognition, endocytosis, and controlled release of the cytotoxic agent, ensuring selective tumor destruction.

The first FDA-approved Antibody-Drug Conjugates, gemtuzumab ozogamicin (Mylotarg), paved the way in 2000. Since then, continuous advancements in antibody design, linker technology, and payload innovation have positioned Antibody-Drug Conjugates as one of the most dynamic segments in oncology drug development.

Antibody-drug Conjugates (ADCs) in Oncology Competitive landscape
• Jiangsu Hengrui Medicine Co.
• Bio-Thera Solutions
• MediLink Therapeutics
• Byondis
• AbbVie
• Oxford BioTherapeutics
• Iksuda Therapeutics
• Novelty Nobility
• LegoChem Biosciences
• DualityBio
• Lepu Biopharma
• Ambrx
• CSPC ZhongQi Pharmaceutical Technology
• MacroGenics
• ADC Therapeutics
• Genor Biopharma
• CStone Pharmaceuticals
• AstraZeneca
• Alteogen
• Biocity Biopharmaceutics

Unlock Insights on 200+ Companies & 220+ ADC Drugs - Get Your Copy Today - https://www.delveinsight.com/sample-request/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Recent Developments in the Antibody-Drug Conjugates Pipeline
The Antibody-Drug Conjugates pipeline has witnessed remarkable growth, with global pharmaceutical giants and emerging biotech players investing heavily in R&D. The report highlights key recent milestones:
• June 2024 - Hudson Therapeutics announced a collaboration with Shaperon for developing nanobody-based ADCs and radiopharmaceutical therapies.
• June 2024 - The US FDA placed a partial clinical hold on Phase I trial of YL202 due to dose-related risks.
• October 2023 - Daiichi Sankyo and Merck entered a landmark global development agreement for three ADC candidates: patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan.
• May 2023 - Bliss Biopharmaceutical signed a clinical collaboration with Eisai for BB-1701, a HER2-directed Antibody-Drug Conjugates, currently in Phase I/II trials.
• April 2023 - Byondis B.V. published promising preclinical data on BYON3521, a next-generation ADC.
• February 2023 - Gilead Sciences' Trodelvy secured FDA approval for HR+/HER2- breast cancer, based on robust Phase III data, strengthening its global footprint.

Access the Most Comprehensive ADC Pipeline & Market Assessment - Download Report - https://www.delveinsight.com/report-store/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Marketed Antibody-Drug Conjugates Therapies
The report profiles leading marketed Antibody-Drug Conjugates reshaping cancer treatment paradigms:

Trodelvy (sacituzumab govitecan-hziy) - Gilead Sciences
• Target: Trop-2 antigen (expressed in 90%+ breast and bladder cancers).
• Mechanism: Proprietary linker attached to topoisomerase I inhibitor payload (SN-38).
• Approvals: Triple-negative breast cancer (TNBC), HR+/HER2- metastatic breast cancer, and urothelial cancer.
• Global Reach: Approved in 40+ countries, with ongoing regulatory reviews.

Padcev (enfortumab vedotin-ejfv) - Astellas Pharma
• Target: Nectin-4 protein in urothelial cancers.
• Combination Use: Approved with pembrolizumab for advanced/metastatic urothelial cancer.
• Mechanism: Delivers MMAE payload directly to Nectin-4 expressing cells.

Antibody-Drug Conjugates Pipeline Highlights: Promising Therapies in Development
The Antibody-Drug Conjugates pipeline is flourishing, with dozens of Phase II and III candidates across solid tumors and hematological malignancies. Notable Antibody-Drug Conjugates therapies include:
• SHR-A1811 (Jiangsu Hengrui Medicine) - HER2-targeted ADC, currently in Phase III trials for breast cancer and under investigation for lung, gastric, and gynecological cancers.
• Telisotuzumab vedotin (AbbVie) - First-in-class c-Met-targeting ADC, in Phase III trials for non-small cell lung cancer (NSCLC).
• BAT8006 (Bio-Thera Solutions) - Targets FRα, overexpressed in ovarian and other solid tumors, currently in Phase II trials.
• YL202 (MediLink Therapeutics) - HER3-directed ADC, under Phase II development with novel tumor microenvironment activable linker technology.
• BYON3521 (Byondis) - c-MET ADC leveraging proprietary linker-payload platform, in Phase I studies.
• IKS03 (Iksuda Therapeutics) - CD19-targeting ADC for B-cell lymphomas, utilizing a PBD dimer pro-drug payload with enhanced safety and efficacy profile.

Discover Emerging ADC Therapies Reshaping Cancer Care - Get the Report Instantly - https://www.delveinsight.com/sample-request/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Antibody-Drug Conjugates Analytical Perspective by DelveInsight
The Antibody-Drug Conjugates (ADCs) - Competitive Landscape, 2025 report offers:
• Comprehensive company analysis - 200+ players in the Antibody-Drug Conjugates domain.
• Therapeutic and pipeline assessment - detailed profiles by stage, route of administration, and technology platform.
• Inactive Antibody-Drug Conjugates drugs assessment - highlighting discontinued or paused programs.
• Commercial landscape - covering licensing deals, acquisitions, partnerships, and collaborations.
• Emerging trends - such as nanobody-based Antibody-Drug Conjugates, improved linker-payload technologies, and tumor-microenvironment responsive mechanisms.

Key Questions Addressed in the Antibody-Drug Conjugates Pipeline Report
The report answers critical strategic questions shaping Antibody-Drug Conjugates R&D and commercialization, including:
• How many Antibody-Drug Conjugates companies are developing Antibody-Drug Conjugates globally?
• What are the most advanced Antibody-Drug Conjugates candidates currently in late-stage trials?
• Which Antibody-Drug Conjugates companies dominate collaborations, licensing, and M&A activity?
• What are the technological innovations driving next-generation Antibody-Drug Conjugates design?
• Which emerging players are likely to disrupt the oncology Antibody-Drug Conjugates market?
• What are the ongoing clinical trials and their statuses across tumor indications?

Don't Miss Out on the Global ADC Competitive Landscape 2025 - Download Now - https://www.delveinsight.com/sample-request/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Antibody-Drug Conjugates Unmet Needs and Future Outlook
While ADCs offer unprecedented promise in oncology, challenges remain:
• Resistance Mechanisms - Cancer cells may develop escape pathways.
• Toxicity Risks - Dose optimization and linker stability are key to safety.
• Manufacturing Complexities - High technical demands for conjugation processes.
Nevertheless, innovation in payloads, bispecific ADCs, and combination regimens is expected to address these limitations. With more than 220+ candidates under development, the ADC market is poised for exponential growth in the next decade.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.